Eli Lilly damages tripled to $184M in Medicaid rebate fraud case
Fierce Pharma
MAY 10, 2023
Eli Lilly damages tripled to $184M in Medicaid rebate fraud case fkansteiner Wed, 05/10/2023 - 10:25
Sat.May 06, 2023 - Fri.May 12, 2023
307 
B2B Sales Prospecting: What You Need To Know
Spotio
MAY 10, 2023
Business-to-business (B2B) prospecting is the pillar of lead generation. When prospecting for new business, the goal is to identify as many quality prospects as possible. However, B2B sales prospecting strategy is not as easy as it sounds. According to Technology Advice , 70% of marketers at B2B companies reported that “improving lead quality” was the primary concern.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Optimized for Growth? Revenue Management in Pharma
PharmExec
MAY 10, 2023
According to the latest State of Revenue survey of c-suite executives, pharma manufacturers are prioritizing digital transformation while struggling with inflation and supply chain disruptions.
BioNTech’s RNA vaccine sparks potential in pancreatic cancer
Pharmaceutical Technology
MAY 11, 2023
Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later. In the study, 16 patients were treated with a vaccine called autogene cevumeran that contained a maximum of 20 neoantigens, alongside Roche’s anti-PD-L1 immunotherapy Tecentriq (atez
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
After Shkreli's run in with the law, Pharma Bro's former company Vyera files for bankruptcy
Fierce Pharma
MAY 11, 2023
After Shkreli's run in with the law, Pharma Bro's former company Vyera files for bankruptcy fkansteiner Thu, 05/11/2023 - 11:06
Is ChatGPT Healthcare’s Autopilot?
MedCity News
MAY 8, 2023
While human empathy will never be replaced, AI technologies and ChatGPT are providing new possibilities to help healthcare providers engage more efficiently with their patients and streamline administrative duties so physicians can focus more on their patients.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
The emergence of tranq amidst the fentanyl crisis
Pharmaceutical Technology
MAY 9, 2023
In February, the FDA issued an alert restricting the import of the veterinary sedative xylazine or tranq and the ingredients used to make the drug. This followed in the wake of a Drug Enforcement Agency (DEA) Joint Intelligence Report in October 2022, which stated that xylazine is widely available from Chinese suppliers on the internet. According to a June 2022 study, xylazine has been detected in the illicit drug supply in 36 US States, and the DEA has reported that approximately 30% of the f
As pharma fights IRA, Senate moves forward basket of bills aimed at lower drug prices
Fierce Pharma
MAY 12, 2023
As pharma fights IRA, Senate moves forward basket of bills aimed at lower drug prices aliu Fri, 05/12/2023 - 10:48
FDA Approves First Drug for Treating Agitation in Alzheimer’s Patients
MedCity News
MAY 11, 2023
Rexulti, a drug for schizophrenia and depression, now has an additional approval for treating agitation in Alzheimer’s disease patients. The FDA decision makes the Otsuka Pharmaceutical and Lundbeck product the first drug approved for this indication.
Implanted Ultrasound Lets Chemo Access Brain
Medgadget
MAY 12, 2023
Researchers at Northwestern University have trailed an implanted ultrasound device in patients, which is used in combination with microbubbles to transiently open pores in the blood brain barrier, allowing chemo drugs to enter. We have reported on this technique before as a lab-based concept (see flashbacks below), but this is the first time that it has actually been trialed in human patients, in this case patients with glioblastoma, a difficult to treat brain cancer.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
$1.7b acquisition to develop rare haematology therapy
European Pharmaceutical Review
MAY 12, 2023
Swedish Orphan Biovitrum AB (Sobi ® ) has agreed to acquire CTI BioPharma for $1.7 billion, with the intention to advance an oral kinase inhibitor treatment for the rare disease myelofibrosis. Innovative therapies for rare diseases The acquisition will help to drive the growth of CTI’s lead product, kinase inhibitor VONJO ® (pacritinib) “in treating myeloproliferative disease,” stated Dr Adam Craig, President, Chief Executive Officer and Interim Chief Medical Officer of CTI BioPharma
Roche's Vabysmo looks to escalate Eylea fight as FDA takes up review in retinal vein occlusion
Fierce Pharma
MAY 9, 2023
Roche's Vabysmo looks to escalate Eylea fight as FDA takes up review in retinal vein occlusion zbecker Tue, 05/09/2023 - 10:51
Medicare Improperly Paid Providers $348M for Telehealth Psychotherapy Services
MedCity News
MAY 7, 2023
Out of the $1 billion in Medicare payments to providers for psychotherapy services in the first year of Covid-19, $580 million were improper payments, an audit by the Office of Inspector General found. This includes $348 million for telehealth services.
Chest Wearable Provides Key Heart Measurements
Medgadget
MAY 10, 2023
Researchers at the University of Texas at Austin have developed a new chest wearable that can obtain both electrocardiogram and seismocardiogram data from the underlying heart. While basic ECG can be monitored via smart watches, no other wearable combines it with seismocardiography, which would conventionally be obtained by listening to the heart using a stethoscope.
Gilead wins patent battle with US government over HIV PrEP drugs
Pharmaceutical Technology
MAY 10, 2023
Gilead Sciences has emerged victorious in a legal battle with the US government over patents surrounding the HIV pre-exposure prophylaxis (PrEP) drugs Descovy and Truvada following a federal jury’s verdict on May 9. A jury in the Delaware District Court gave a favourable verdict to the Foster City, California-headquartered company, concluding that Gilead did not infringe any of the US government’s patents.
Pfizer, AstraZeneca run it back in IDEA Pharma's annual innovation rankings
Fierce Pharma
MAY 8, 2023
Pfizer, AstraZeneca run it back in IDEA Pharma's annual innovation rankings kdunleavy Mon, 05/08/2023 - 10:21
FDA’s Landmark Guidance on Decentralized Clinical Trials (DCTs) Signals a New Era of Patient-Centered Research
MedCity News
MAY 11, 2023
With the FDA’s acceptance and encouragement of decentralized trials, we can expect to see a continued shift towards remote trial conduct, virtual sites, and the use of innovative digital technologies.
FDA publishes paper on AI/ML in drug development
European Pharmaceutical Review
MAY 11, 2023
The US Food and Drug Administration (FDA) has released a discussion paper to complement and inform future guidance on artificial intelligence (AI) and machine learning (ML) in drug development. The paper is intended to initiate communication with stakeholders, including industry and academia, to foster mutual learning and discussion. The questions in Section B aim to initiate a discussion with stakeholders and solicit feedback on three key areas in the context of AI/ML in drug development.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Ginkgo and Boehringer partner to develop hard-to-treat disease therapies
Pharmaceutical Technology
MAY 9, 2023
Ginkgo Bioworks and Boehringer Ingelheim have collaborated to develop breakthrough therapies for hard-to-treat diseases. The companies will use the natural product discovery capabilities of Ginkgo Bioworks to expedite the discovery and development of new therapeutic molecules to address diseases with high unmet patient needs. They will also use the metagenomic sequence database of Ginkgo Bioworks which comprises more than three terabases of sequence data and over two billion protein sequences fr
As COVID vaccine sales plummet, BioNTech looks for new growth opportunities
Fierce Pharma
MAY 8, 2023
As COVID vaccine sales plummet, BioNTech looks for new growth opportunities zbecker Mon, 05/08/2023 - 11:02
Medical Affairs’ Role in Driving Adherence to Evidence-Based Medicine
MedCity News
MAY 10, 2023
Medical Affairs plays a critical role when it comes to driving adherence to evidence-based medicine (EBM) – the principle that clinical decisions should be informed by the best available scientific evidence, along with clinical experience and patient preference.
Enzyme replacement therapy approved for Fabry disease
European Pharmaceutical Review
MAY 8, 2023
A marketing authorisation for PRX-102 (pegunigalsidase alfa) , the first Poly(ethylene glycol) (PEG)ylated enzyme for Fabry disease, has been granted by the European Commission (EC). The approval follows the European Medicines Agency (EMA) human medicines committee’s recommendation of the enzyme replacement therapy (ERT) in February 2023. CHMP recommends first pegylated enzyme for Fabry disease… The PEGylated enzyme replacement therapy Chiesi Global Rare Diseases and Protalix BioTherapeutics, In
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Synlogic’s SYNB1934 receives orphan drug status from US FDA
Pharmaceutical Technology
MAY 10, 2023
Synlogic has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for SYNB1934 to treat phenylketonuria (PKU), a rare inherited metabolic disease. The orally administered, non-systemically absorbed drug candidate SYNB1934 has been designed for reducing blood phenylalanine (Phe) levels in PKU patients. SYNB1934 consumes Phe in the gastrointestinal (GI) tract by leveraging genetic engineering of the drug or drug-carrying capsule, probiotic escherichia coli (E coli)
Sanofi, AstraZeneca strengthen case for RSV antibody with data from real-world trial
Fierce Pharma
MAY 11, 2023
Sanofi, AstraZeneca strengthen case for RSV antibody with data from real-world trial kdunleavy Thu, 05/11/2023 - 15:23
California Lawmakers Approve Emergency Loan Program for Struggling Hospitals
MedCity News
MAY 7, 2023
California lawmakers recently passed a bill that would provide interest-free cash loans to nonprofit and public hospitals undergoing significant financial distress. The loan program would provide up to $150 million in funds over the next couple years.
Wearable Ultrasound Measures Tissue Stiffness Under Skin
Medgadget
MAY 12, 2023
Researchers at the University of California San Diego have developed a wearable ultrasound patch that is intended to provide information on the stiffness of underlying tissues as deep as 4 cm below the surface of the skin. The patch consists of a flexible 16 x 16 ultrasonic array with a silver-epoxy composite backing layer that is designed to absorb excessive vibrations.
How to Stay Competitive in the Evolving State of Martech
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Researchers develop CRISPR-based drug candidate for microbiome targeting
Pharmaceutical Technology
MAY 12, 2023
The Technical University of Denmark (DTU) has announced that an international scientific team has developed a CRISPR-based drug candidate that targets E coli directly and leaves the microbiome intact. Blood cancer patients with E coli infection are at risk of bacteria infecting the bloodstream. An E coli infection can be fatal in these cases, with a 15-20% mortality rate.
Novartis targets underserved fields—and CAR-T—for next phase of immunology growth: exec
Fierce Pharma
MAY 10, 2023
Novartis targets underserved fields—and CAR-T—for next phase of immunology growth: exec aliu Wed, 05/10/2023 - 12:08
Uncovering Inequity in Cancer Care Among the LGBTQ+ Community
MedCity News
MAY 12, 2023
Although conversations around other LGBTQ+ issues are prevalent in mainstream culture, more work needs to be done on understanding our screening, treatment, and survivorship.
Could personalised mRNA vaccine be first for cancer?
European Pharmaceutical Review
MAY 12, 2023
A BioNTech-led Phase I trial demonstrated preliminary evidence that adjuvant autogene cevumeran, a personalised mRNA neoantigen vaccine, in combination with atezolizumab (Genentech) and mFOLFIRINOX can induce substantial T cell activity in pancreatic ductal adenocarcinoma (PDAC). In a paper published in Nature , researchers hypothesised it may correlate with delayed recurrence and elimination of micrometastases in PDAC.
Let's personalize your content